Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma
Cancer Immunology, Immunotherapy · 04.06.2024 · 73 (8)
DOI: 10.1007/s00262-024-03745-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 04.06.2024. Verfasst von Xinyuan Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, …. Hauptthemen laut MEDLINE: B7-H1 Antigen, Carcinoma, Pancreatic Ductal, Promoter Regions, Genetic, DNA Methylation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Outstanding Youth Science Fund Project of National Natural Science Foundation of China.
Abstract (Originalsprache)
Despite the successful application of programmed cell death ligand 1 (PD-L1)-blocking strategies in some types of cancers and well-established prognostic indicators in pancreatic ductal adenocarcinoma (PDAC), the biological and clinical implications of the methylation status of PD-L1/PD-L2 in PDAC remain largely unknown. Therefore, this study aimed to explore the biological role of PD-L1/PD-L2 methylation and its association with clinicopathological features, clinical outcomes, and the immune microenvironment by analyzing the data on PD-L1/PD-L2 methylation and mRNA expression in PDAC cohorts obtained from the Cancer Genome Atlas and International Cancer Genome Consortium. The correlation between PD-L1 promoter methylation and PD-L1 expression and survival was further validated in an independent validation cohort (Peking Union Medical College Hospital [PUMCH] cohort) using pyrosequencing and immunohistochemistry. These results demonstrated that hypomethylation of the PD-L1 promoter was strongly associated with upregulated PD-L1 expression and shorter overall survival in PDAC. Multivariate Cox regression analyses revealed that the PD-L1 promoter methylation was an independent prognostic factor. PD-L1 promoter hypomethylation and high expression were related to aggressive clinical phenotypes. Moreover, both PD-L1 and PD-L2 methylation correlated with immune cell infiltration and the expression of immune checkpoint genes. PD-L1 promoter methylation status was further validated as an independent prognostic biomarker in patients with PDAC using the PUMCH cohort. The prognostic significance of PD-L1 promoter methylation was more discriminative in tumors with perineural/lymphovascular invasion and distant metastasis than in those without perineural/lymphovascular invasion and distant metastasis. In summary, the methylation status of the PD-L1 promoter is a promising biomarker for survival outcomes, immune infiltration, and the potential immune benefits of immunotherapy in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
- 4+4 Medical Doctor Program, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China. chenjie@pumch.cn.
- Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China. xlchen1995@sina.com.
Förderung
- National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
Zitieren
APA
Chen, X., Yu, S., Chen, J., & Chen, X. (2024). Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma. Cancer Immunology, Immunotherapy, 73(8). https://doi.org/10.1007/s00262-024-03745-y
Vancouver
Chen X, Yu S, Chen J, Chen X. Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma. Cancer Immunology, Immunotherapy. 2024;73(8). doi:10.1007/s00262-024-03745-y
BibTeX
@article{Chen2024,
author = {Chen, Xinyuan and Yu, Shuangni and Chen, Jie and Chen, Xianlong},
title = {Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
volume = {73},
number = {8},
doi = {10.1007/s00262-024-03745-y}
}
EUVIMED